Table 1 Structures of N-glycans in the stria vascularis.

From: Characterisation of N-glycans in the epithelial-like tissue of the rat cochlea

Fraction No.

Rstria

Sstria

Rstd or Rcalc

Sstd or Scalc

Relative amount

Assigned structure

N

1

31.757

8.37

32.7

8.4

27.1

Man8GlcNAc2:(M8)

2

33.304

7.51

34.4

7.5

12.8

Man7GlcNAc2:(M7)

3

35.137

9.05

36.4

9.1

32.3

Man9GlcNAc2:(M9)

4-1

38.140

7.46

39.4

7.5

10.4

Man7GlcNAc2:(M7)

4-2

38.140

8.21

38.7

8.2

3.0

Man8GlcNAc2:(M8)

5

40.152

6.64

41.2

6.6

100.0

Man6GlcNAc2:(M6)

6-1

42.858

3.15

43.1

3.2

7.7

Man2GlcNAc2:(M2)

6-2

42.858

6.02

44.5

6.1

4.0

GlcNAcMan5GlcNAc2:(GnM5)

7-1

43.755

4.11

44.5

4.1

9.0

Man3GlcNAc2:(M3)

7-2

43.755

5.01

43.7

5.0

5.2

Man4GlcNAc2:(M4)

8-1

45.266

5.80

46.2

5.8

67.2

Man5GlcNAc2:(M5)

8-2

45.266

7.30

47.0

7.3

4.2

Man7GlcNAc2:(M7)

8-3

45.266

9.67

47.0

9.8

2.9

GluMan9GlcNAc2:(G1M9)

10

49.780

6.48

  

2.0

Ac-Man9GlcNAc2:(Ac-M9)

11-1

51.191

4.87

52.3

4.9

2.4

GlcNAc2Man3GlcNAc2:(AG12)

12-1

52.739

3.55

51.5

3.4

8.0

Man2FucGlcNAc2:(M2F6)

12-2

53.507

4.45

54.0

4.4

10.0

Man3FucGlcNAc2:(M3F6)

12-3

53.507

5.61

53.7

5.6

11.5

GlcNAc2Man4GlcNAc2:(GnM4Bs)

14-2

55.595

6.31

56.3

6.4

7.7

Gal2GlcNAc2Man3GlcNAc2:(BI)

15

56.807

4.89

  

3.7

Ac-Man6GlcNAc2:(Ac-M6)

16-1

58.699

5.62

  

2.1

Ac-Man5GlcNAc2:(Ac-M5)

16-2

58.699

6.48

  

2.0

GalGlcNAcHexNAc3Man3GlcNAc2:(Hex4HexNAc6)

17

59.934

5.12

60.3

5.1

2.2

GlcNAc2Man3FucGlcNAc2:(AG12F6)

20

64.501

5.17

64.7

5.2

3.9

GlcNAc2Man3FucGlcNAc2:(AG2BsF6)

21-1

66.000

5.16

66.6

5.2

17.8

GlcNAc3Man3GlcNAc2:(AG12Bs)

21-2

66.000

7.39

  

2.3

Gal2GlcNAc2HexNAc2Man3FucGlcNAc2:(Hex5HexNAc6dHex)

22-1

68.153

5.80

70.2

5.8

5.6

GalGlcNAc3Man3GlcNAc2:(BIBs-G2)

22-2

68.153

6.69

  

3.4

GalGlcNAc4Man3FucGlcNAc2:(TEF6-3G)

25

76.047

5.38

76.1

5.4

12.8

GlcNAc3Man3FucGlcNAc2:(AG12BsF6)

26

78.263

5.97

78.4

6.0

6.9

GalGlcNAc3Man3FucGlcNAc2:(BIBsF6-G1)

27

79.883

6.65

80.0

6.7

2.6

Gal2GlcNAc3Man3FucGlcNAc2:(BIBsF6)

A1

2

53.324

5.83

55.3

6.0

6.5

NeuAcGalGlcNAcMan3GlcNAc2:(6N-MO1)

3-1

54.312

6.47

56.2

6.6

26.9

NeuAcGalGlcNAcMan4GlcNAc2:(6N-LnM4)

3-2

54.312

7.24

56.6

7.4

55.8

NeuAcGalGlcNAcMan5GlcNAc2:(6N-LnM5)

4-1

58.874

6.03

61.2

5.9

3.0

NeuAcGalGlcNAcMan4GlcNAc2:(3N-LnM4)

4-2

58.874

6.74

60.7

6.9

9.0

NeuAcGalGlcNAcMan5GlcNAc2:(3N-LnM5)

5

59.998

6.05

61.7

6.1

4.1

NeuAcGalGlcNAc2Man3GlcNAc2:(06N-BI-G2)

6

61.064

8.07

62.6

8.4

2.4

NeuAcGal3GlcNAc3Man3FucGlcNAc2:(06N-TRF6)

8-1

62.732

6.06

62.9

6.1

4.6

NeuAcGalGlcNAcMan3FucGlcNAc2:(6N-MO1F6)

8-2

62.732

6.71

64.9

6.5

9.9

NeuAcGalGlcNAcMan4FucGlcNAc2:(6N-LnM4F6)

8-3

62.732

7.42

64.4

7.5

3.1

NeuAcGalGlcNAcMan5FucGlcNAc2:(6N-LnM5F6)

9

64.148

5.96

67.2

5.7

2.8

NeuAcGalGlcNAc2Man3GlcNAc2:(03N-BI-G2)

11

67.625

5.89

69.4

5.9

2.5

NeuAcGalNAcGlcNAc2Man3FucGlcNAc2: [06N-BI(mLdn1)F6-G2]

12

68.806

6.28

71.0

6.4

5.9

NeuAcGalGlcNAc2Man3FucGlcNAc2:(06N-BIF6-G2)

13

70.422

6.93

72.5

7.1

4.0

NeuAcGal2GlcNAc2Man3FucGlcNAc2:(06N-BIF6)

14-1

71.278

6.30

74.4

6.4

2.2

NeuAcGalGlcNAc3Man3GlcNAc2:(06N-BIBs-G2)

14-2

71.278

7.61

72.2

7.6

2.7

NeuAcGal3GlcNAc2Man3FucGlcNAc2:(06N-Gaβ42-BIF6)

17-1

75.313

6.02

76.6

5.9

2.2

NeuAcGalGlcNAcMan3FucGlcNAc2:(6N-MO2F6)

17-2

75.313

6.49

76.4

6.6

2.8

NeuAcGal2GlcNAc2Man3FucGlcNAc2:(30N-BIF6)

18

76.811

5.57

77.7

5.6

2.9

NeuAcGalGlcNAcMan3FucGlcNAc2:(3N-MO2F6)

19

79.040

6.08

78.9

6.2

3.4

NeuAcGalGlcNAc3Man3GlcNAc2:(60-BIBs-G1)

20

81.076

6.55

82.7

6.6

3.8

NeuAcGalGlcNAc3Man3FucGlcNAc2:(06N-BIBsF6-G2)

21

84.022

7.10

86.2

7.2

3.4

NeuAcGal2GlcNAc3Man3FucGlcNA2:(06N-BIBsF6)

22

86.338

6.29

89.1

6.5

5.9

NeuAcGalGlcNAc3Man3FucGlcNAc2:(06-BIBsF6-G2)

A2

14-1

71.510

7.11

75.2

7.3

21.9

NeuAc2Gal2GlcNAc2Man3GlcNAc2:(66N-BI)

14-2

71.510

7.83

  

2.1

NeuAc2Gal3GlcNAc3Man3FucGlcNAc2:(dN-TRF6)

15

73.106

6.68

76.5

6.9

4.8

NeuAc2Gal2GlcNAc2Man3GlcNAc2:(36N-BI)

16-1

75.619

8.04

  

2.2

NeuAc2Gal3GlcNAc4Man3FucGlcNAc2:(dN-TEF6-1G or dN-TRBsF6)

16-2

75.619

8.61

  

3.4

NeuAc2Gal4GlcNAc4Man3FucGlcNAc2:(dN-TEF6)

17

76.989

6.89

79.8

7.1

8.1

NeuAc2GalGalNAcGlcNAc2Man3FucGlcNAc2: [66N-BI(mLdn1)F6]

18

77.890

7.32

81.4

7.5

19.2

NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(66N-BIF6)

19

79.027

6.60

82.0

6.8

2.7

NeuAc2Gal2GlcNAc2Man3FucGlcNAc2: [66N-BI(dLdn1,2)F6]

20

80.969

6.90

84.2

7.1

8.5

NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(36N-BIF6)

23

85.992

6.54

89.0

6.7

5.0

NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(33N-BIF6)

24

90.046

7.46

  

6.4

NeuAc2Gal2GlcNAc3Man3FucGlcNAc2:(dN-BIBsF6 or dN-TRF6-1G)

25

93.339

6.92

  

5.1

NeuAc2Gal2GlcNAc3Man3FucGlcNAc2:(dN-BIBsF6 or dN-TRF6-1G)

27

99.235

6.50

  

2.1

NeuAc2Gal2GlcNAc2Man3FucGlcNAc2:(dN-BIBsF6 or dN-TRF6-1G)

A3

10

77.082

8.11

  

2.9

NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6)

12

79.491

7.81

  

5.2

NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6)

13

81.419

5.59

  

2.8

SO3−-NeuAcGalNAc2GlcNAc2Man3FucGlcNAc2: [SO3−6N-BI(dLdn1,2)F6]

14

82.500

7.40

  

2.9

NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6)

15-1

83.595

7.93

  

3.1

NeuAc3Gal3GlcNAc3Man3GlcNAc2:(trN-TR)

15-2-1

83.595

8.52

  

1.2

NeuAc3Gal3GlcNAc4Man3FucGlcNAc2:(trN-TRBsF6 or trN-TEF6-1G)

15-2-2

83.595

8.52

  

2.7

NeuAc3Gal3GlcNAc4Man3FucGlcNAc2:(trN-TRBsF6 or trN-TEF6-1G)

15-3-1

83.595

8.95

  

1.5

NeuAc3Gal4GlcNAc4Man3FucGlcNAc2:(trN-TEF6)

15-3-2

83.595

8.95

  

1.6

NeuAc3Gal4GlcNAc4Man3FucGlcNA2:(trN-TEF6)

18

90.797

8.05

  

7.6

NeuAc3Gal3GlcNAc3Man3FucGlcNAc2:(trN-TRF6)

A4

6

88.863

8.88

  

2.1

NeuAc4Gal4GlcNAc4Man3FucGlcNAc2:(teN-TEF6)

7

90.864

8.54

  

2.2

NeuAc4Gal4GlcNAc4Man3FucGlcNAc2:(teN-TEF6)

  1. Possible structures and names of individual 79 N-glycans identified in the present study are listed with the R and S values of the strial samples (Rstria and Sstria), the R and S values of the standard glycans (Rstd and Sstd: Bold) or those calculated based on empirical additivity rule and MS data of the strial glycan (Rcalc and Scalc: Italic) and relative amounts [toward the amount of N-5 (Man6GlcNAc2, i.e. M6)]. Following data are described in Supplementary Table S2; peak areas of the glycan fractions obtained by size fractionation HPLC, total peak intensity of A3-15-2-1, A3-15-2-2, A3-15-3-1, and A3-15-3-2 in positive ion mode MALDI-QIT-TOF-MS analysis, the m/z values detected in LC-ESI-MS spectrum, the m/z values described in mass databases, the ion types detected in LC-ESI-MS analysis and symbolic images of the glycan structures.
Back to article page